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A major challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development is to elicit potent and
broadly neutralizing antibodies that are effective against primary viral isolates. Previously, we showed that DNA
prime-protein boost vaccination using HIV-1 gp120 antigens was more effective in eliciting neutralizing antibodies
against primary HIV-1 isolates than was a recombinant gp120 protein-only vaccination approach. In the current
study, we analyzed the difference in antibody specificities in rabbit sera elicited by these two immunization regimens
using peptide enzyme-linked immunosorbent assay and a competitive virus capture assay. Our results indicate that
a DNA prime-protein boost regimen is more effective than a protein-alone vaccination approach in inducing
antibodies that target two key neutralizing domains: the V3 loop and the CD4 binding site. In particular, positive
antibodies targeting several peptides that overlap with the known CD4 binding area were detected only in DNA-
primed sera. Different profiles of antibody specificities provide insight into the mechanisms behind the elicitation
of better neutralizing antibodies with the DNA prime-protein boost approach, and our results support the use of this
approach to further optimize Env formulations for HIV vaccine development.
AIDS remains one of the largest human epidemics affecting
the world today. More than 33 million people are currently
living with human immunodeficiency virus type 1 (HIV-1), the
virus that causes AIDS, with an estimated 2.5 million new
infections occurring in 2007 alone. Over 20 million deaths have
already been attributed to HIV-1 infection (http://www.who.int
/hiv/mediacenter/news62/en/index.html). The best hope of con-
trolling this epidemic is the development of a successful pro-
phylactic vaccine. Recent setbacks from the STEP trial (36),
which relied purely on the induction of cell-mediated immune
responses, further highlight the need to develop vaccines that
can elicit neutralizing antibodies (NAbs) against primary
HIV-1 isolates. Unfortunately, eliciting a strong NAb response
to the virus has proven to be an exceptionally difficult task.
Natural HIV-1 infection usually results in strong antibody
responses against the viral envelope protein (Env). However,
only weak heterologous neutralization is observed in most
HIV-positive patient sera. HIV employs a number of strategies
to escape neutralization pressure from the host. One of these
is the high variability of Env, which allows the virus to escape
from NAbs (31, 45). Epitope masking by variable loops, high
levels of glycosylation, and quaternary interactions resulting
from the trimerization of Env also play significant roles (28).
Despite this, several broadly neutralizing monoclonal antibod-
ies (MAbs) that target conserved regions of Env have been
identified (3, 4, 47). Two of these antibodies, 2G12 and immu-
noglobulin G1b12 (IgG1b12 [b12]), recognize gp120, the sur-
face subunit of Env. 2G12 targets specific carbohydrate
epitopes on the heavily glycosylated silent face of gp120, while
b12 targets the CD4 binding site (CD4bs) (46). Other broadly
neutralizing MAbs, 2F5, Z13, and 4E10, target the membrane-
proximal external region of gp41 (25, 49). The V3 region of
Env is frequently masked in primary isolate Env trimers; there-
fore, antibodies targeted to this region usually have only lim-
ited neutralization breadth and potency against primary HIV-1
isolates (29). In light of studies showing that broad NAbs,
administered as passive immunizations, are able to prevent
infection in nonhuman primate challenge models (5, 12, 14, 20,
21), attempts to elicit similar NAbs through active immuniza-
tion have become a major focus of HIV vaccine development.
We previously reported that DNA prime-protein boost vac-
cination successfully elicited NAbs against the primary HIV-1
isolate JR-FL, a relatively neutralization-resistant virus (39).
Rabbits were first inoculated with a DNA vaccine expressing
the JR-FL gp120 antigen, followed by a boost with the homol-
ogous recombinant gp120, produced in CHO cells. While the
control group, which received the JR-FL gp120 protein vaccine
alone, induced NAbs against sensitive HIV-1 isolates, only sera
from the group that received the DNA prime-protein boost
elicited detectable neutralizing activity against the JR-FL virus
in both human peripheral blood mononuclear cell (PBMC)-
and cell line-based neutralization assays (39). Subsequently,
using the same DNA prime-protein boost approach, we dem-
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onstrated that polyvalent Env formulations containing Env an-
tigens from diverse genetic backgrounds elicited low-titer but
broad NAbs against a subset of pseudotyped viruses expressing
primary HIV-1 Env antigens from clade A, B, C, D, and E
isolates (44).
In the current study, we investigated the profiles of antibody
specificities from these two different vaccination approaches in
an attempt to explain the differences in neutralization activity.
We analyzed sera from two studies: one from our published
study using the monovalent JR-FL gp120 antigen (39) and
another that employed a polyvalent gp120 formulation that
was recently evaluated in a phase I clinical trial with human
volunteers (43).
MATERIALS AND METHODS
Rabbit immunizations. Rabbit sera against the monovalent JR-FL gp120
antigen were generated in a previous study (39). We also generated rabbit sera
in the current study with the same polyvalent primary gp120 formulation used in
our recent clinical study (43). Briefly, female New Zealand White rabbits, 6 to 8
weeks old (2 kg body weight), were purchased from Millbrook Farm (Amherst,
MA) and housed in the animal facility managed by the Department of Animal
Medicine at the University of Massachusetts Medical School. Groups of rabbits
were immunized with a pentavalent gp120 DNA vaccine at weeks 0, 4, and 12 and
boosted with the homologous pentavalent gp120 proteins at weeks 20 and 28.
The control protein-alone group received an empty DNA vector at weeks 0, 4,
and 12 and the same pentavalent gp120 proteins at weeks 20 and 28. This
formulation includes gp120 antigens from subtype A (92UG037.8), B
(92US715.6 and Bal), C (96ZM651), and E (93TH976.17) HIV-1 isolates. The
DNA vaccine components were produced by subcloning the five codon-opti-
mized gp120 genes, individually, into the DNA vaccine vector pSW3891 (40).
The gp120 DNA vaccine plasmids or the empty pSW3891 vector plasmid were
coated onto 1.0-m gold beads at a ratio of 2 g of DNA per mg of gold and
delivered to the animals via a Bio-Rad Helios gene gun on shaved abdominal
skin (42). Each animal received 36 g of total DNA plasmids at each immuni-
zation. The five recombinant gp120 proteins were produced in CHO cell lines
(27) and purified with a laboratory-based system using lectin to concentrate the
gp120 proteins. Recombinant gp120, in doses of 100 g, were administered
intradermally in incomplete Freund’s adjuvant (Sigma). Sera were collected
immediately before and 2 weeks after each immunization.
Antibodies. MAbs IgG1b12, b6, and X5 were obtained from Dennis Burton.
MAbs 39F, 7B2, LE311, and 15e were all obtained from James Robinson. 2G12
was obtained from Hermann Katinger.
Viruses. Pseudotypings of env genes from 92RW020, 92TH021, 92UG046,
93IN905, 94UG103, 94UG114, 98CN006, CMU02, JR-CSF,MN, NL4-3, PVO.4,
QH0692.42, SC422661.8, AC10.0.29, and SF162 for the PhenoSense assay were
all performed at Monogram Biosciences. The HIV-1 env genes from SF162,
SC422661.8, and SS1196 and the pSG3Env backbone, used for pseudotyping as
part of the in-house neutralization assay, were obtained through the NIH AIDS
Research and Reference Reagent Program.
Enzyme-linked immunosorbent assay (ELISA). Microtiter plates (96 wells)
were coated with 100 l of individual overlapping 15-mer peptides (4 g/ml)
derived from the consensus HIV-1 M-group gp120 sequence, obtained from the
NIH HIV reference reagent program (catalog number 9487). Plates were incu-
bated at room temperature for 1 h, washed five times with 200 l wash buffer
(0.1% Triton-X in phosphate-buffered saline [PBS]), and blocked overnight in
4% whey dilution buffer containing 1% (by weight) powdered milk. Plates were
washed again and incubated with 100 l rabbit sera normalized to 200 ng/ml
gp120-specific IgG for 1 h at room temperature. Plates were washed again and
incubated with 100 l of 1 g/ml biotinylated anti-rabbit antibody (BA-1000;
Vector Labs) for 1 h at room temperature. After additional washes, 100 l of 500
ng/ml horseradish peroxidase-conjugated streptavidin (SA-5004; Vector Labs)
was added for 1 h at room temperature. Plates were washed and developed for
3.5 min in 100 l of a 3,3,5,5-tetramethylbenzidine substrate solution (TMB-
E-100; ViroLabs). The reaction was stopped by the addition of 25 l 2 N H2SO4
to the mixture. Plates were then read using a Dynex OpSys MR plate reader.
The rabbit sera were normalized using a semiquantitative ELISA to determine
the concentration of gp120-specific IgG in each sample. The gp120 used to coat
plates was matched to the immunogen used for rabbit study, i.e., either JR-FL
gp120 alone (5 g/ml) or a pentavalent mixture (1 g/ml of each component).
The concentration of gp120-specific IgG in each serum sample was determined
against a standard curve generated using known rabbit IgG (catalog number
0111-01; Southern Biotechnology Associates), as previously described (41). Rab-
bit sera were prepared to normalized concentrations of 200 ng/ml of gp120-
specific IgG.
Virus capture competition. Various assays of virus capture by HIV-1 MAbs
have been described in literature (24, 26, 30). In the current study, the ability of
rabbit sera to inhibit the capture of pseudovirions by various MAbs was inves-
tigated using a previously described assay (6, 10). Pseudotyped virions in this
assay expressing both HIV-1 Env and vesicular stomatitis virus G protein on the
virion surface were produced. The vesicular stomatitis virus G protein will me-
diate the entry of virions into the target cell line CF2.CD4.CCR5 irrespective of
any neutralizing activity against the HIV envelope present in the sera, thus
providing a sensitive readout of captured virus as previously described (24). The
capture of pseudovirions by HIV-1 MAbs will be blocked if there is a competing
antibody in the rabbit sera. Specifically, microwells were coated with individual
MAbs (5 g/ml) overnight and were then washed and blocked with 3% bovine
serum albumin in PBS. Graded dilutions of rabbit sera were added to the virus,
and the virus-serum mixtures were then added to MAb-coated ELISA wells for
3 h, followed by washing with PBS. CF2.CD4.CCR5 cells were overlaid, and 2
days later, infection was measured by assaying luciferase. The reciprocal serum
dilution that inhibited MAb-mediated virus capture by 50% was recorded.
Neutralization assays. Neutralization was determined by three separate but
similar assays. The first assay measured the p24 reduction in PBMC with the
monovalent JR-FL Env serum as previously reported (23, 39) The second assay
was conducted through a subcontract using the PhenoSense assay system (31). In
this system, pseudovirus was harvested 48 h after cotransfecting HEK293 cells
with pCXAS-Env libraries plus an HIV genomic vector that contains a firefly
luciferase indicator gene. Pseudoviruses were then incubated with heat-inacti-
vated rabbit sera at graded dilutions for 1 h at 37°C. U87 cells expressing CD4
and the CCR5 and CXCR4 coreceptors were inoculated with virus-antibody
mixtures in the absence of added cations. Virus infectivity was determined 72 h
postinoculation by measuring the amount of luciferase activity expressed in
infected cells. Neutralizing activity was calculated as the percent inhibition of
viral replication (luciferase activity) at each antibody dilution compared with a
rabbit serum-free control as follows: % inhibition  [1  (luciferase  immune
sera)/(luciferase immune sera)] 100. Prebleed rabbit sera were also included
as negative controls. Murine leukemia virus was also included in each assay to
rule out nonspecific neutralizing activities. The third assay, the in-house neutral-
ization assay, was performed as previously described (22). Pseudovirus was gen-
erated by the cotransfection of a gp160 envelope with the pSG3Env backbone.
Pseudotyped virus was added at 200 50% tissue culture infective doses/well and
incubated with rabbit sera at 37°C for 1 h. TZM-bl cells were then seeded at
10,000 cells/well in a final concentration of 20 g/ml DEAE-dextran. Plates were
incubated at 37°C for 48 h and then developed with luciferase assay reagent
according to the manufacturer’s instructions (Promega). Neutralization was cal-
culated as the percent reduction in luciferase activity in the presence of rabbit
immune sera compared to the luciferase activity induced by the virus in the
presence of preimmune sera as follows: [1  (luciferase  immune sera)/(lucif-
erase  preimmune sera)]  100 (10).
In peptide adsorption experiments, the same in-house neutralization assay was
conducted with one additional step: first incubating rabbit sera with or without 30
g/ml of peptide for 1 h at 37°C. The percent reduction in neutralization was
calculated as follows: [1  (NAb titer in the presence of peptide)/(NAb titer in
the absence of peptide)]  100.
BN-PAGE. To analyze antibody binding to Env trimers, we investigated anti-
body binding to native, virion-derived trimers by a modified blue native poly-
acrylamide gel electrophoresis (BN-PAGE) protocol as previously described (6,
24). Virus-like particles were mixed with rabbit sera for 5 min. To liberate Env,
virus-like particles were incubated in an equal volume of solubilization buffer
(0.12% Triton X-100 in 1 mM EDTA–1.5 M aminocaproic acid) and 1 l of a
protease inhibitor cocktail (Sigma). An equal volume of 2 sample buffer con-
taining 100 mM morpholinepropanesulfonic acid (MOPS), 100 mM Tris-HCl
(pH 7.7), 40% glycerol, and 0.1% Coomassie blue was then added. Samples were
loaded onto a 4% to 12% Bis-Tris NuPAGE gel (Invitrogen). Ferritin (Amer-
sham) was used as a size standard. Samples were electrophoresed at 4°C for 3 h
at 100 V with 50 mM MOPS–50 mM Tris (pH 7.7) containing 0.002% Coomassie
blue as a cathode buffer and the same buffer without Coomassie blue as the
anode buffer. The gel was then blotted onto polyvinylidene difluoride. Excess
Coomassie blue dye was removed by washing the membrane with 30% metha-
nol–10% acetic acid, followed by 100% methanol. The blot was then transferred
into blocking buffer (4% nonfat milk in PBS) for 30 min and probed using 1
g/ml each of MAbs 2G12, b12, and 447-52D (anti-gp120 cocktail). Goat anti-
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human and/or anti-mouse Fc alkaline phosphatase conjugates were used, as
appropriate, to detect the primary MAbs at a dilution of 1:3,000 (Jackson Lab-
oratories). The density of native and liganded Env bands was determined using
ImageJ software, v. 1.33u (NIH freeware; http://rsb.info.nih.gov/ij/). The anti-
body dilution was recorded as that in the final sample at the time of loading.
RESULTS
Detection of antibodies recognizing conformational V3
epitopes and the CD4bs in monovalent DNA prime-protein boost
HIV vaccine sera. We previously observed that both the DNA
prime-protein boost and protein-alone vaccination regimens
elicit high titers of anti-Env antibodies in New Zealand White
rabbits; however, only sera from the DNA prime-protein boost
group effectively neutralized isolate JR-FL (39). This observa-
tion is supported by studies from several groups who provided
evidence that DNA prime-protein boosting more effectively
elicits NAbs against JR-FL and other primary HIV-1 viruses
than does protein alone (1, 16, 44).
Two rabbit sera (rabbit number 120 [R#120] and R#121)
from the DNA prime-protein boost group and two from the
protein-alone group (R#186 and R#187), reported in a pre-
vious study (39), were included in the current study. The anti-
gp120 IgG titers were very similar between the DNA prime-
protein boost and protein-alone sera (Fig. 1A). However,
positive NAb titers against JR-FL were found only in the group
that received the DNA prime (Fig. 1B) (39). Mapping using a
panel of overlapping peptides derived from the V3 region of
JR-FL Env antigen, 15 amino acids (aa) in length with 11 aa of
overlap (see Table S1 in the supplemental material), revealed
that every V3 peptide recognized by the DNA prime-protein
boost sera was also recognized by the protein-only sera (Fig.
1C). A more than twofold greater IgG titer was found in the
protein-alone sera than in the DNA prime-protein boost sera
against peptide 3, suggesting that linear V3 epitopes are well
preserved in recombinant gp120 antigens. Overall, there was
no significant reactivity to the V1/V2 region peptides for either
type of rabbit sera (Fig. 1C).
We next performed virus capture competition experiments
using various MAbs including three MAbs (b6, 15e, and b12)
against the CD4bs, two (39F and LE311) against the V3 loop,
one (2G12) specific for carbohydrate, one (X5) recognizing a
CD4-inducible epitope (CD4i), and one (7B2) specific for the
gp41 cluster I region of Env, which also served as a negative
control since the rabbits were immunized with gp120 (Fig. 1D).
Similar to the peptide ELISAs, high titers of antibodies com-
peting with MAbs LE311 and 39F for binding to the V3 loop
were found in both immunization groups. However, different
from the peptide ELISAs, the titers were two- to fivefold
higher in sera from DNA-primed animals than in sera from the
protein-alone group (Fig. 1D). This difference may reflect the
fact that the viral particle-based competition assay preserves
Env conformation. Therefore, the DNA prime-protein boost
approach appears to induce more antibodies against confor-
mation-dependent V3 epitopes.
More importantly, high levels of antibodies that compete
against three CD4bs-specific MAbs were found in DNA prime-
protein boost sera (Fig. 1D). DNA prime-protein boost sera were
positive for b6- and 15e-like antibodies; however, these same
antibodies were undetectable in protein-only immune sera. The
DNA-primed sera also competed for binding to b12 at titers
approaching 1:1,000, while sera from the group immunized with
protein only could not compete for binding at detectable levels
FIG. 1. Antibody responses elicited from immunization with JR-FL in a DNA prime-protein boost or protein-alone immunization regimen.
(A) Anti-gp120 IgG endpoint binding titers as measured by ELISA. (B) NAb titers against JR-FL at 50% neutralization of the virus as seen in
a PBMC-based neutralization assay. An  indicates that less than 50% neutralization was seen at a starting dilution of 1:10. (C) Serum recognition
of linear peptides derived from the V1/V2 and V3 regions of JR-FL among DNA prime-protein boost and protein-alone rabbit sera. The lowest
serum dilution tested was 1:100. (D) Virus capture competition assay using seven MAbs specific for domains on HIV-1 Env and sera from both
DNA prime-protein-boosted and protein-immunization-alone animals. Antibody levels are reported as titers necessary to prevent 50% of virus
binding. Data shown are average titers, with bars indicating standard deviations of data from rabbits in each group. An * indicates that no antibody
competition was detected.
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(Fig. 1D). Competition assays using MAbs 2G12 and 7B2 re-
vealed no antibodies against either epitope (Fig. 1D).
Eliciting NAbs in rabbit sera using a polyvalent DNA prime-
protein boost Env vaccine formulation, DP6-001. In our pre-
clinical and clinical immunogenicity studies, we reported that
polyvalent gp120 formulations, delivered by the DNA prime-
protein boost approach, elicited NAbs that were effective
against viruses belonging to several different major subtypes of
HIV-1 (43, 44). To further investigate the antibody specificities
induced by the DNA prime-protein boost regimens, we immu-
nized rabbits with the same pentavalent gp120 vaccine formu-
lation (DP6-001) that induced low-titer but positive NAbs
against a wide range of primary Env antigens in a recently
completed phase I clinical study (43). New Zealand White
rabbits were immunized with either a DNA prime-protein
boost or protein-alone regimen with the pentavalent gp120
formulation as shown in Fig. 2. Sera collected from rabbits 2
weeks after the second protein boost in both groups were used
to evaluate peak-level gp120-specific IgG and NAb responses.
The peak-level gp120-specific binding titers were very simi-
lar between the two immunization groups (Fig. 3). However,
sera from rabbits that received the polyvalent DNA prime-
protein boost showed higher neutralizing activities against a
panel of pseudotyped viruses in the PhenoSense assay (Table
1). Here, we examined three sensitive viruses (MN, NL4-3, and
SF162) and 12 viruses that are relatively resistant to neutral-
ization with Env antigens derived from primary isolates of
clades A, B, C, D, and E. Serum dilution was started at 1:10,
but positive neutralizing activities (defined as 	50% inhibi-
tion) at a serum dilution of 1:30 are summarized to reflect a
more stringent cutoff for scoring positive responses and to
exclude nonspecific inhibitions in this assay. All sera, regard-
less of the immunization regimen, neutralized the tier 1 sensi-
tive isolates MN, NL4-3, and SF162 at this serum dilution. Sera
from the DNA prime-protein boost group also neutralized 8
out of the 12 more resistant viruses. Neutralization of primary
isolates from clades A, C, and D was observed in almost every
case in the DNA-primed rabbit sera. Three viruses (AC10.0.29,
PVO.4, and QH0692.42) from the NIH tier 2 clade B stan-
dardized panel (17) and JR-CSF (another neutralization-resis-
tant isolate) were not neutralized by any of the rabbit sera
(data not shown). Two rabbit sera had neutralizing activity
against SC422661.8 from the NIH tier 2 clade B standardized
panel. Clade E isolate 92TH021 was neutralized by only two
out of four DNA-primed sera. In contrast, sera from rabbits
immunized with protein only did not neutralize most of the
primary viruses. At a 1:30 serum dilution, no inhibition of
murine leukemia virus infection was observed (data not
shown), demonstrating that the neutralization was HIV-1 spe-
cific. Additionally, a broadly neutralizing human serum, N16,
was used as a positive control. This serum neutralized all pri-
mary isolates with titers between 1:30 and 1:90 (data not
shown). Preimmune rabbit sera were also included as a nega-
tive control for the PhenoSense assay. No neutralization was
observed with the preimmune sera at a 1:30 serum dilution.
Epitope mapping of the polyvalent sera using linear over-
lapping peptides. To determine any difference in antibody
specificities between DNA-primed versus protein-alone poly-
valent rabbit sera, we first measured serum binding to linear
15-mer peptides with 11-residue overlaps derived from the
group M consensus gp120 sequence (catalog number 9487;
NIH AIDS Reference and Reagent Program). To test this,
rabbit sera was normalized to equivalent total gp120-specific
IgG titers. Sera from both groups had strong reactivity to
peptides derived from the C1, C2, V3, and C5 segments of
gp120 (Fig. 4), including two prominent regions within the N
terminus of the V3 loop, which is similar to the peptide binding
results, as measured by ELISA using monovalent JR-FL-
immunized rabbit sera (Fig. 1C). Very little reactivity was
observed against peptides derived from the V1/V2 and V4
loops of gp120 for any of the sera tested.
Interestingly, rabbit sera from the DNA-primed group ex-
hibited unique positive binding against six regions that were
FIG. 2. Immunization groups and pentavalent gp120 vaccine for-
mulation. Rabbits received either DNA prime-protein boost or pro-
tein-alone immunizations. An * indicates the HIV-1 primary isolates
from which the gp120 vaccine components were derived.
FIG. 3. gp120-specific IgG titers in rabbits immunized with DNA
prime-protein boost and protein-alone formulations against autolo-
gous antigens as measured by ELISA. Data are shown as geometric
mean titers, with bars indicating standard deviations of data from two
or four rabbits in the group immunized with protein alone or the group
immunized with DNA plus protein, respectively. “Prebleed” and “Post
Protein-2” indicate the sera collected at preimmunization and at 2
weeks after the second protein immunization, respectively.
TABLE 1. NAb responses elicited by polyvalent Env formulationsa
HIV-1 isolate
(subtype)
% Neutralization for vaccine group:
DNA prime  protein boost Protein alone
29-1 29-2 30-1 30-2 33-1 33-2
MN (B) 99.9 99.9 99.9 99.9 99.1 92.7
NL4-3 (B) 97.6 98.6 99.7 96 94.3 93.9
SF162 (B) 99.9 99.9 99.9 99.9 99.8 98.4
92RW020 (A) 54 57.5 55.6 50.4 — —
94UG103 (A) — 51 51.6 55.4 — —
SC422661.8 (B) — 58.6 — 56.4 — —
93IN905 (C) 62.1 66.6 66.7 63.3 — 59.2
98CN006 (C) 53 56.1 — 50 — —
92UG046 (D) 53.4 56.1 54.7 54.1 — —
94UG114 (D) 57.2 57.7 55.2 60.3 — —
92TH021 (E) — — 51.9 53.9 — 50.2
a The data are shown as percent neutralization at a 1:30 serum dilution as
determined by the PhenoSense neutralization assay. —, less than 50% inhibition.
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poorly recognized by the protein-only sera (see arrows in Fig.
4). The sizes of these six regions vary: peptides 11 (p11) and 30
(p30) were recognized as single peptides, p48/p49 and p56/p67
were recognized as two adjacent peptides, and p61 to p64 and
p113 to p117 were recognized as clusters of several neighbor-
ing peptides. Further analysis of these six highly reactive re-
gions indicated that three of them, p30, p61 to p64, and p113
to p117, contain amino acid residues that either are part of the
CD4bs or are involved in binding with the neutralizing MAb
b12 based on a previously published Env structure (15, 46).
The sequences of these peptides are listed in Fig. 5A. The
average levels of binding of rabbit sera from the two immu-
nized groups to these peptides were compared. Sera from the
DNA prime-protein boost group had significantly greater rec-
FIG. 4. gp120 peptide-specific IgG responses as measured by ELISA. The red and black curves indicate rabbit sera from DNA prime-protein
boost or protein-alone immunization with polyvalent vaccine, respectively. Rabbit sera were normalized to equivalent gp120 binding titers. The
gp120 peptides were linear overlapping peptides derived from the group M consensus gp120 sequence of HIV-1. Data shown are the average
optical density (OD) values for two rabbits in the protein-alone group or four rabbits in the group immunized with DNA plus protein. Arrows
indicate positive binding responses unique to the DNA-primed group against six different regions (i.e., no positive responses were observed in the
protein-alone group). These six regions include the regions at p11, p30, p48 to p49, p56 to p57, p61 to p64, and p113 to p117.
FIG. 5. Additional analysis of three highly reactive regions of gp120. (A) Recognition of linear peptides that contain CD4 or b12 contact
residues by DNA-primed or protein-alone rabbit sera as measured by ELISA. Bars represent the average optical density (OD) values with standard
deviations for two rabbits in the protein-alone group or four rabbits in the group immunized with DNA plus protein against each peptide listed
on the right. (B) Locations of group M consensus linear peptides (blue) overlaid onto the crystal structure of JR-FL gp120 liganded with CD4 and
MAb X5. CD4 contact residues are highlighted in red. (C) Locations of group M consensus linear peptides (blue) overlaid onto the crystal structure
of JR-FL gp120 liganded with CD4 and MAb X5. b12 contact residues are highlighted in orange.
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ognition of these three regions than did sera from the protein-
alone group (P 
 0.01) (Fig. 5A). The overlay of these se-
quences onto the crystal structure of gp120 demonstrates that
the locations of these peptides (in blue) are in the known CD4
binding region on gp120, overlapping with either the above-
described CD4bs (Fig. 5B, red) or b12 binding residues (Fig.
5C, orange).
Because a polyvalent Env formulation was used in this rabbit
immunization study and because the sequence differences of
these Env proteins, particularly in the variable loops, may have
precluded the recognition of the consensus M peptides, we
generated overlapping peptides (20-mer peptides with 10 aa
overlapping) for each of the variable loops from four primary
gp120 antigens that were used in our study: 92UG037 (clade
A), 92US715 (clade B), 96ZM651 (clade C), and 93TH976
(clade E) (see Table S2 in the supplemental material). These
peptides were then tested for antibody recognition with the
polyvalent rabbit sera by ELISA. Some sequence-specific vari-
able-loop recognition was observed in sera from immunized
rabbits against peptides derived from the V1/V2 loop of clade
A and E Env antigens, in contrast to peptides derived from the
V1/V2 loop of clade B and C Env antigens. However, there was
no differential recognition in this region between the DNA-
primed and protein-alone groups. Reactivity was also found in
the V3 loop for both the group immunized with the DNA
prime-protein boost and the group immunized with protein
alone; however, the locations of these recognized epitopes
differed between Env antigens. The recognition of the V3 loop
was more focused on the N-terminal side and crown of the V3
loop for the clade A Env, on the crown of the V3 loop for the
clade E Env, and on the crown and C-terminal strand for the
clade C Env and was evenly distributed against the V3 loop of
the clade B Env (Fig. 6). Once again, very little reactivity
against peptides in V4 region was generated (Fig. 6). For the
V5 region, it is striking to find that there are 1 to 2 peptides,
located at the junction of the V5 and C5 regions, that were
recognized by the sera elicited with the DNA prime-protein
boost approach but not the protein-alone sera (Fig. 6). Pep-
tides 17 and 18 in Fig. 6 correspond to the amino acid se-
quences included in peptides 115 to 117 as shown in Fig. 4 and
are therefore in the region involved in CD4 binding (Fig. 5)
(32).
Mapping polyvalent sera by virus capture competition. Com-
petitive virus capture was used to further map antibody spec-
ificities. Titers of 39F- and LE311-like antibodies (V3 loop
specific) were much higher in animals that received a DNA
prime (Fig. 7); this mirrors the pattern observed with the
monovalent sera (Fig. 1C and D) but contradicts data from the
peptide ELISAs (Fig. 4 and 5). Additionally, the competitive
virus capture assay revealed higher titers of CD4bs-specific
antibodies (15e and b12) in animals that received a DNA
prime compared to those who received protein-only immuni-
zations.
The data described here demonstrate that the DNA prime-
FIG. 6. Polyvalent rabbit serum recognition of peptide sequences derived from the variable loops V1/V2, V3, V4, and V5 from individual gp120
proteins of the polyvalent vaccine components as measured by ELISA. Rabbits were immunized with DNA prime-protein boost (gray bars) or
protein only (white bars). Peptides from gp120 A, B, C, and E were used in graphs A, B, C, and D, respectively. Bars represent the average optical
density (OD) values for two rabbits in the protein-alone group or four rabbits receiving DNA plus protein against each peptide. Peptide sequences
are shown in Table S2 in the supplemental material.
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protein boost approach is more effective in eliciting conforma-
tional V3 and CD4bs antibodies than the protein-alone approach.
However, these data do not prove that these antibodies are re-
sponsible for the improved NAb activities observed in the DNA-
primed rabbit sera (Table 1). To elucidate the roles of the ele-
vated V3 antibodies in the neutralization of HIV isolates, we
attempted to adsorb the V3-specific antibodies by incubating the
sera with 15-mer clade B consensus peptides spanning the N-
terminal strand of the V3 loop (TRPNNNTRKSIHIGPGRAF).
This region was chosen because several recent studies indicated
that this area is the target of several neutralizing V3 MAbs (2,
33–35). A pilot experiment was conducted to confirm that these
peptides were capable of adsorbing V3-mediated neutralizing ac-
tivity in rabbit sera by using a control rabbit serum that was
immunized with only a V3 peptide fused with a carrier protein
(48). V3 peptide adsorption of this serum resulted in a
greater than 95% decrease in the neutralizing activity
against pseudotyped virus expressing Env from HIV-1 iso-
late SF162, an isolate very sensitive to V3-mediated neu-
tralization (Fig. 8A).
When sera from the polyvalent DNA prime-protein boost
rabbits were first incubated with these V3 peptides and then
tested for their neutralizing activities against pseudotyped virus
expressing Env from HIV-1 isolate SF162, we observed that
the sera isolated from DNA prime-protein-boosted animals
were more sensitive to a depletion in neutralization (Fig. 8B).
Sera from rabbits that received a DNA prime had an average
of 79% reduction in NAb titers, compared to the 50% reduc-
tion in animals that received protein-only-based immuniza-
tions. The greater sensitivity of the DNA-primed sera to V3
peptide adsorptions supports the above-described data that
V3-directed antibodies are present in higher levels in DNA-
primed animals. We next addressed the role of V3-mediated
antibodies in the neutralization of more resistant primary iso-
lates. We repeated the V3 peptide adsorptions in an attempt to
neutralize two clade B primary isolates, SS1196 (Fig. 9A) and
SC422661.8 (Fig. 9B). V3 peptide adsorption had very little
effect on the neutralization of SS1196: only an average of 9%
reduction in neutralization was observed. Additionally, no re-
duction in neutralization was observed in the presence of com-
peting V3 peptide with the other primary isolate, SC422661.8.
This indicates that while V3 antibody levels may be elevated in
the DNA-primed animals, they play a minimal role in the
neutralization of more resistant primary isolates. This leaves
the increased levels of CD4bs antibodies or other unknown
conformational antibodies as possible candidates responsible
FIG. 8. Effect of V3 peptide adsorption on neutralization of HIV-1
isolate SF162. Clade B consensus overlapping peptides corresponding to
the N-terminal strand and crown of the V3 loop were pooled and incu-
bated with sera at 30 g/ml prior to exposure to pseudotyped virus ex-
pressing Env from HIV-1 isolate SF162. Neutralization titers indicate the
serum dilution that can achieve a 50% inhibition of virus infection. (A) Ef-
fect of peptide adsorption on the neutralizing activity of sera from a rabbit
immunized with only a V3 fusion protein as a control. Error bars indicate
standard deviations of data from a one-time multiwell neutralization as-
say. (B) Effect of V3 peptide adsorption on the neutralizing activity of
individual rabbit sera from polyvalent DNA prime-protein boost (29-1,
29-2, 30-1, and 30-2) and protein-alone immunizations (33-1 and 33-2).
Error bars indicate standard deviations from replicate experiments.
FIG. 7. Detection of antibody specificities in DNA-primed or pro-
tein-alone polyvalent rabbit sera. This competitive virus capture assay
used MAbs to study the specificities and titers of antibodies present in
the polyvalent sera. Bars indicate the average dilutions of sera for two
rabbits in the protein-alone group or four rabbits in the group receiv-
ing DNA plus protein, resulting in a 50% reduction in virus binding.
Error bars indicate standard deviations within the group. Significance
was calculated using a one-tailed Student’s t test. *, P 
 0.05.
FIG. 9. Effect of V3 peptide adsorption on neutralization of primary
HIV-1 isolates. Clade B consensus overlapping peptides corresponding to
the N-terminal strand and crown of the V3 loop were pooled and incu-
bated with sera at 30 g/ml prior to exposure to pseudotyped virus.
Percent neutralization at a 1:10 dilution of rabbit sera is reported. “Pro-
tein Alone” and “DNA  Protein” indicate rabbits receiving polyvalent
protein-alone (33-1 and 33-2) or DNA prime-protein boost (29-1, 29-2,
30-1, and 30-2) immunization, respectively. (A) Effect of V3 adsorption on
neutralization of HIV-1 clade B virus SS1196. (B) Effect of V3 adsorption
on neutralization of HIV-1 clade B virus SC422661.8. Error bars indicate
standard deviations from replicate experiments.
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for the enhanced neutralizing activities of the DNA-primed
sera against more resistant primary viral isolates (Table 1).
DNA-primed rabbit sera have higher gp120 trimer binding
abilities. Finally, we measured serum binding to native Env
trimers thought to be crucial for neutralization (24). Trimer
binding was measured by the depletion of unliganded trimers
in a BN-PAGE assay. Only sera from rabbits that received the
DNA prime-protein boost immunizations, particularly C29-1,
effectively depleted unliganded trimers (Fig. 10). These data
support neutralization results showing that the DNA prime-
protein boost immunization strategy elicits more effective NAb
responses.
DISCUSSION
Most of our understanding on the specificities of NAbs
against HIV-1 has been learned through the study of a few
broad NAbs (4) and, more recently, through the mapping of
neutralizing epitope specificities in HIV-infected people (7, 8,
11, 13, 18). One key neutralizing epitope that has been iden-
tified is the CD4bs of gp120. Antibodies specific for this
epitope have been shown to be responsible for the activities of
broadly neutralizing human sera (18, 32). One MAb, b12, spe-
cific for the CD4bs, is known to be capable of neutralizing
primary patient isolates. Therefore, the CD4bs is a vulnerable
site that could serve as a target for NAbs in HIV vaccine
design.
Because the CD4bs is a conformational site formed by res-
idues that are far apart from each other based on the gp120
primary sequence, it is exciting to observe increased levels of
CD4bs antibodies in immune sera from the DNA prime-pro-
tein boost gp120-vaccinated rabbits in the current study. This
was seen in both the monovalent and polyvalent gp120 formu-
lations, indicating a consistent advantage of the DNA priming
approach. This finding implies that a DNA priming step may
be effective in preserving conformationally sensitive epitopes
and/or that this step is important for priming a subset of B cells
specific for CD4bs epitopes, which are responsive to a subse-
quent gp120 protein boost. Due to the relatively low neutral-
izing titers in rabbit immune sera, we could not definitively
prove that CD4bs antibodies are in fact responsible for the
neutralization of primary isolates by using the gp120 protein
absorption method reported in a recent study (18). However,
using peptide absorption experiments, we ruled out a possible
contribution by V3-specific antibodies, leaving anti-CD4bs an-
tibodies, among other conformationally sensitive epitopes, as a
likely explanation for the neutralizing activity.
Our study identified one particular highly reactive region,
involving multiple adjacent peptides, at the junction of the V5
and C5 regions. This region of gp120 includes both the CD4
and b12 binding epitopes as determined by sequence align-
ment against previously reported HIV-1 Env structures (15).
This reactivity to the V5-C5 region is highly conserved, as it
can be observed in different peptides derived from four gp120
proteins of different clades included in the polyvalent gp120
formulation. This was seen despite the fact that the exact
amino acid sequences of these peptides were not identical.
This result highlights the uniqueness of this site and excludes
the possibility that one dominant peptide is responsible for a
high level of recognition against the M-group consensus pep-
tides. Future studies with additional primary Env antigens
should prove whether this region is important for other pri-
mary HIV-1 isolates.
We also observed that the DNA prime-protein boost regi-
men induced higher anti-V3 antibodies in rabbit immune sera.
High-level V3-specific antibodies were responsible for the neu-
tralizing activities against the sensitive isolate SF162 but gen-
erally not for other primary isolates. It is also interesting that
polyvalent rabbit immune sera showed different binding pref-
erences for subdomains of the V3 loops from gp120 proteins of
different clades of HIV-1. Our results suggest that the V3 loops
of different clades are oriented differently and therefore elicit
different specificities. Most of the previously reported data on
V3 antibodies are based on clade B viruses; however, recently,
several studies indicated that different V3 sequences bind dif-
ferently to various V3-specific MAbs (2, 33–35). The DNA
prime-protein boost vaccination approach, which induces
higher levels of anti-V3 antibodies, provides a practical
method to understand the fine specificity of V3 antibodies that
recognize Env antigens from different clades.
A trimer gel shift assay demonstrated the presence of anti-
bodies that are capable of recognizing the trimeric form of
HIV-1 Env in our DNA-primed sera. Sera from DNA-primed
animals bound native trimers more efficiently than did sera
collected from animals that were immunized with protein only.
Since the binding of native trimers predicts neutralization,
trimer recognition by DNA-primed sera correlates with in-
creased neutralization activity. Collectively, with improved
CD4bs and V3 antibodies, the trimer gel shift results further
confirm that a DNA priming step may increase the levels of
neutralization for a vaccine formulation by focusing the serum
antibody responses to a more favorable specificity profile.
Previous studies demonstrated that antibody induced by one
subtype E antigen, rgp120CM235, preferentially binds natively
folded gp120 and retains strong cross-reactivity against multi-
ple gp120 strains within subtype E as well as against strains
FIG. 10. Binding of rabbit immune sera to HIV-1 JR-FL Env tri-
mers by BN-PAGE analysis. Sera from either DNA prime-protein
boost immunization (29-1 and 30-1) or protein-only immunization
(33-1 and 33-2) were incubated with solubilized trimers prior to being
run on a BN-PAGE gel. Numbers below each lane indicate the per-
centage of unliganded trimer present in the gel based upon densitom-
etry analysis.
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from subtype B (38). In contrast, in that same study, antibody
responses to another gp120 from isolate SF2 were shown to be
directed predominantly toward linear epitopes that are poorly
exposed on native gp120, and it was also shown that these
antibodies have a more limited ability to cross-recognize di-
vergent gp120. Similarly, an antibody response preferentially
reactive with natively folded gp120/gp160 was dependent on
immunization conditions that preserved the structure of the
HIV-1 envelope immunogen (37). Several primary HIV-1 iso-
lates were neutralized in that study, which used Env antigens
purified directly from cultured HIV-1 viruses, but recombinant
protein-based Env antigens used in another study could induce
antibodies that could neutralize only T-cell-line-adapted
HIV-1 but not primary isolates (38). Analysis of the MAbs
elicited by trimeric protein-based HIV-1 gp140 immunogens
with modified Env sequences did not reveal neutralizing activ-
ity against heterologous primary viruses, suggesting that a par-
ticular immunogen was unable to elicit antibodies that can bind
to native forms of Env (9). Previously, the same virus capture
competition used in the current study was performed to ana-
lyze monkey sera from either modified SF162 gp140 immuni-
zations or SHIVSF162P4 infection. Minimal CD4bs- or V3-di-
rected antibodies were seen using the modified gp140
immunogens. However, very high levels of CD4bs- and V3-
directed antibodies were observed in the simian/human immu-
nodeficiency virus-infected animals (10), a pattern that is very
similar to what we saw in the current study using the natural
gp120 immunogens in a DNA prime-protein boost approach.
Therefore, an immunization approach that can preserve natu-
ral Env epitopes is critical to elicit NAbs.
In order to compensate for the weak immunogenicity of
primary Env proteins, strong adjuvants are frequently required
in order for recombinant Env proteins to first elicit high-titer
antibody responses in experimental animals before any neu-
tralizing activities can be studied (19, 37). In our rabbit studies,
a conventional incomplete Freund’s adjuvant was used at the
protein boost step with both the monovalent and polyvalent
Env formulations. This implies another advantage of the DNA
prime-protein boost approach in that DNA immunization can
effectively prime the antigen-specific B cells, which can in turn
respond with a high-level antibody response upon administra-
tion of the protein boost without the need for a particularly
powerful adjuvant. Furthermore, the variation of antibody re-
sponses within a study group is minimal with DNA priming
compared to that with immunization with protein alone (1).
Although these results originated from a small-animal study,
it is again interesting that similar patterns of antibody recog-
nition were seen in two entirely independent studies. Given
this observation, additional work with increased sample sizes
and in higher-primate models would be useful in confirming
that the observed pattern remains consistent. In summary, we
analyzed the antibody profiles induced by a DNA prime-pro-
tein boost vaccination approach and discovered that antibody
specificities against key neutralizing epitopes are improved
with this approach. Given the increasing evidence that CD4bs-
specific antibodies are responsible for broad neutralization, as
discovered in HIV-infected patients with potent and broad
NAb responses, the DNA prime-protein boost vaccine ap-
proach offers an attractive platform for the development of
next-generation HIV vaccines that focus on broad NAbs.
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